Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients – A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study

Date

09 Oct 2016

Session

Poster display

Presenters

Hsiang-Fong Kao

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

H. Kao1, C. Hsiao2, S. Lai2, C. Wang1, J. Ko3, P. Lo3, T. Lee1, T. Liu4, R. Hong1

Author affiliations

  • 1 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 2 Institute Of Population Health Sciences, National Health Research Institutes, 35053 - Miao-Li/TW
  • 3 Department Of Otorhinolaryngology, National Taiwan University Hospital, 100 - Taipei/TW
  • 4 National Health Research Institutes, Taiwan Cooperative Oncology Group, 115 - Taipei/TW
More

Resources

Background

Pre-treatment plasma EBV DNA is considered as a prognostic biomarker for NPC patients. Whether the pre-treatment EBV DNA could be a biomarker guiding the treatment for advanced NPC patients warrants investigation.

Methods

TCOG 1303 was a phase III trial comparing induction chemotherapy (IC) followed by concurrent chemoradiation (CCRT) versus CCRT alone in stage IVA or IVB NPC patients. In both arms, radiotherapy would be delivered with weekly cisplatin (30mg/m2). For patients in IC arm, chemotherapy with mitomycin C, epirubicin, cisplatin, 5-fluorouracil, and leucovorin were administered for 3 cycles before the CCRT. The primary endpoint was disease free survival. Pre-treatment plasma EBV DNA was analyzed.

Results

From September 2003 to August 2009, 479 patients were enrolled. The pre-treatment plasma EBV DNA were collected from 264 patients. The median follow-up were 66 months. The median of plasma EBV DNA was 7862.5 copies/mL. 135 pts were grouped in EBV DNA =  8000 copies/mL (EBV-high). High plasma EBV DNA is statistically significant with larger tumor size (p 

Conclusions

Pre-treatment plasma EBV DNA cannot be a biomarker of induction MEPFL for stage IVA or IVB NPC patients. The biology role of pre-treatment EBV DNA should be explored.

Clinical trial identification

NCT00201396

Legal entity responsible for the study

Hsiang-Fong Kao

Funding

National Taiwan University Hospital, Taiwan National Health Research Institutes, Taiwan

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings